Peptides as signaling inhibitors for mammalian MAP kinase cascades.

Mammalian MAPK cascades are essential for cellular signaling in response to mitogenic signals and stress-stimuli to regulate proliferation, differentiation and apoptosis. The three major MAPK cascades, ERK1/2-, JNK- and p38, maintain signaling specificity by scaffolding proteins and by specific docking interactions between pathway components. The structures mediating these interactions include the domain of versatile docking (DVD) responsible for MAP3K-MAP2K-interaction and the common docking (CD)-domain and the ED (glutamate/aspartate)-site of MAPKs together with the various docking (D) motifs in MAP2Ks, MAPK substrates and MAPK-phosphatases. Several of these interactions have been studied in great detail. First approaches to use this knowledge to develop peptides that specifically inhibit MAPK signaling in disease models have been reported. It becomes obvious that specificity of peptides competing with kinase-docking is comparable to or even superior to small molecule ATP-competitive inhibitors. In addition to specifically targeting protein-protein interactions, the ultimate efficacy of these peptide inhibitors in vivo also depends on their delivery, stability and toxicity in living cells and in the whole organism.

[1]  M. Cobb,et al.  MEKK1 Binds Directly to the c-Jun N-terminal Kinases/Stress-activated Protein Kinases* , 1997, The Journal of Biological Chemistry.

[2]  Francesca Zazzeroni,et al.  Gadd45β mediates the NF-κB suppression of JNK signalling by targeting MKK7/JNKK2 , 2004, Nature Cell Biology.

[3]  S. Meloche,et al.  Atypical mitogen-activated protein kinases: structure, regulation and functions. , 2007, Biochimica et biophysica acta.

[4]  J. Blenis,et al.  Spatially Separate Docking Sites on ERK2 Regulate Distinct Signaling Events In Vivo , 2005, Current Biology.

[5]  P. Rakic,et al.  Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene , 1997, Nature.

[6]  E. Nishida,et al.  Interaction of MAP kinase with MAP kinase kinase: its possible role in the control of nucleocytoplasmic transport of MAP kinase , 1997, The EMBO journal.

[7]  M E Greenberg,et al.  A cytoplasmic inhibitor of the JNK signal transduction pathway. , 1997, Science.

[8]  G. Baillie,et al.  ERK2 Mitogen-activated Protein Kinase Binding, Phosphorylation, and Regulation of the PDE4D cAMP-specific Phosphodiesterases , 2000, The Journal of Biological Chemistry.

[9]  L. Bardwell,et al.  Mechanisms of MAPK signalling specificity. , 2006, Biochemical Society transactions.

[10]  She Chen,et al.  Structural insights into the enzymatic mechanism of the pathogenic MAPK phosphothreonine lyase. , 2007, Molecular cell.

[11]  Rey-Huei Chen,et al.  Molecular interpretation of ERK signal duration by immediate early gene products , 2002, Nature Cell Biology.

[12]  Y. Abu-Amer,et al.  Inhibition of inflammatory bone erosion by constitutively active STAT-6 through blockade of JNK and NF-kappaB activation. , 2005, Arthritis and rheumatism.

[13]  A. Sharrocks,et al.  Differential targeting of MAP kinases to the ETS‐domain transcription factor Elk‐1 , 1998, The EMBO journal.

[14]  D. Lambright,et al.  MAP Kinase Signaling Specificity , 2002, Science.

[15]  J. Blenis,et al.  ERK and p38 MAPK-Activated Protein Kinases: a Family of Protein Kinases with Diverse Biological Functions , 2004, Microbiology and Molecular Biology Reviews.

[16]  T. Aigaki,et al.  The RING‐finger scaffold protein Plenty of SH3s targets TAK1 to control immunity signalling in Drosophila , 2005, EMBO reports.

[17]  E. Nishida,et al.  A Novel MAPK Phosphatase MKP-7 Acts Preferentially on JNK/SAPK and p38α and β MAPKs* , 2001, The Journal of Biological Chemistry.

[18]  M. Karin,et al.  Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. , 1993, Genes & development.

[19]  Radha Akella,et al.  Crystal structures of MAP kinase p38 complexed to the docking sites on its nuclear substrate MEF2A and activator MKK3b. , 2002, Molecular cell.

[20]  A. Ullrich,et al.  PTP‐SL and STEP protein tyrosine phosphatases regulate the activation of the extracellular signal‐regulated kinases ERK1 and ERK2 by association through a kinase interaction motif , 1998, The EMBO journal.

[21]  L. Greene,et al.  POSH acts as a scaffold for a multiprotein complex that mediates JNK activation in apoptosis , 2003, The EMBO journal.

[22]  P. Cohen,et al.  Specificity and mechanism of action of some commonly used protein kinase inhibitors , 2000 .

[23]  A. Gavin,et al.  A MAP kinase docking site is required for phosphorylation and activation of p90rsk/MAPKAP kinase-1 , 1999, Current Biology.

[24]  C. Pargellis,et al.  Catalysis and Function of the p38α·MK2a Signaling Complex , 2004 .

[25]  S. Ghosh,et al.  Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex , 2000 .

[26]  W. Kolch.  Coordinating ERK/MAPK signalling through scaffolds and inhibitors , 2005, Nature Reviews Molecular Cell Biology.

[27]  F. de Ribaupierre,et al.  A Peptide Inhibitor of C-jun N-terminal Kinase Protects against Both Aminoglycoside and Acoustic Trauma-induced Auditory Hair Cell Death and Hearing Loss , 2022 .

[28]  O. Dittrich‐Breiholz,et al.  Disruption of the c-JUN-JNK Complex by a Cell-permeable Peptide Containing the c-JUN δ Domain Induces Apoptosis and Affects a Distinct Set of Interleukin-1-induced Inflammatory Genes* , 2003, Journal of Biological Chemistry.

[29]  E. Wagner,et al.  Antagonistic control of cell fates by JNK and p38-MAPK signaling , 2008, Cell Death and Differentiation.

[30]  L. Greene,et al.  Direct Interaction of the Molecular Scaffolds POSH and JIP Is Required for Apoptotic Activation of JNKs* , 2006, Journal of Biological Chemistry.

[31]  R. Davis,et al.  Structural organization of MAP-kinase signaling modules by scaffold proteins in yeast and mammals. , 1998, Trends in biochemical sciences.

[32]  M. Karin,et al.  JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain , 1994, Cell.

[33]  M. Gaestel,et al.  Constitutive Activation of Mitogen-activated Protein Kinase-activated Protein Kinase 2 by Mutation of Phosphorylation Sites and an A-helix Motif (*) , 1995, The Journal of Biological Chemistry.

[34]  Steven F Dowdy,et al.  Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis , 2004, Nature Medicine.

[35]  Sam-Yong Park,et al.  Structural basis for the selective inhibition of JNK1 by the scaffolding protein JIP1 and SP600125 , 2004, The EMBO journal.

[36]  P. Rakic,et al.  Requirement of JIP scaffold proteins for NMDA-mediated signal transduction. , 2007, Genes & development.

[37]  S. Goueli,et al.  Selective in Vivo Inhibition of Mitogen-activated Protein Kinase Activation Using Cell-permeable Peptides* 210 , 2002, The Journal of Biological Chemistry.

[38]  Roger J. Davis,et al.  The JIP Group of Mitogen-Activated Protein Kinase Scaffold Proteins , 1999, Molecular and Cellular Biology.

[39]  A. Eshraghi,et al.  Blocking c-Jun-N-terminal kinase signaling can prevent hearing loss induced by both electrode insertion trauma and neomycin ototoxicity , 2007, Hearing Research.

[40]  T. Sturgill,et al.  Creation of a Stress-activated p90 Ribosomal S6 Kinase , 2000, The Journal of Biological Chemistry.

[41]  Christian Haslinger,et al.  p38α suppresses normal and cancer cell proliferation by antagonizing the JNK–c-Jun pathway , 2007, Nature Genetics.

[42]  K Kornfeld,et al.  Multiple docking sites on substrate proteins form a modular system that mediates recognition by ERK MAP kinase. , 1999, Genes & development.

[43]  J. Yasuda,et al.  A mammalian scaffold complex that selectively mediates MAP kinase activation. , 1998, Science.

[44]  A. Prochiantz,et al.  Transduction peptides: from technology to physiology , 2004, Nature Cell Biology.

[45]  I. Decosterd,et al.  A Peptide c-Jun N-Terminal Kinase (JNK) Inhibitor Blocks Mechanical Allodynia after Spinal Nerve Ligation: Respective Roles of JNK Activation in Primary Sensory Neurons and Spinal Astrocytes for Neuropathic Pain Development and Maintenance , 2006, The Journal of Neuroscience.

[46]  K. Hayess,et al.  Effect of protein kinase inhibitors on activity of mammalian small heat-shock protein (HSP25) kinase. , 1997, Biochemical pharmacology.

[47]  H. McLeod,et al.  The kinetics and tissue distribution of protein transduction in mice. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[48]  M. Repici,et al.  Role of the JNK pathway in NMDA-mediated excitotoxicity of cortical neurons , 2007, Cell Death and Differentiation.

[49]  S. Taylor,et al.  Protein kinase inhibition: natural and synthetic variations on a theme. , 1997, Current opinion in chemical biology.

[50]  P. Cohen,et al.  The specificities of protein kinase inhibitors: an update. , 2003, The Biochemical journal.

[51]  K. Tyler,et al.  Novel Strategy for Treatment of Viral Central Nervous System Infection by Using a Cell-Permeating Inhibitor of c-Jun N-Terminal Kinase , 2007, Journal of Virology.

[52]  J. Virkkala,et al.  Rescue of Hearing, Auditory Hair Cells, and Neurons by CEP-1347/KT7515, an Inhibitor of c-Jun N-Terminal Kinase Activation , 2000, The Journal of Neuroscience.

[53]  H. Muniyappa,et al.  Activation of c-Jun N-terminal kinase (JNK) by widely used specific p38 MAPK inhibitors SB202190 and SB203580: a MLK-3-MKK7-dependent mechanism. , 2008, Cellular signalling.

[54]  K. Asadullah,et al.  Protein kinases as small molecule inhibitor targets in inflammation. , 2007, Current medicinal chemistry.

[55]  P. Rakic,et al.  Requirement of the JIP1 scaffold protein for stress-induced JNK activation. , 2001, Genes & development.

[56]  E. Nishida,et al.  A conserved docking motif in MAP kinases common to substrates, activators and regulators , 2000, Nature Cell Biology.

[57]  D. Neuberg,et al.  Disruption of the Jnk2 (Mapk9) gene reduces destructive insulitis and diabetes in a mouse model of type I diabetes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[58]  S. Ghosh,et al.  Use of cell permeable NBD peptides for suppression of inflammation , 2006, Annals of the rheumatic diseases.

[59]  A. Eshraghi,et al.  D-JNKI-1 treatment prevents the progression of hearing loss in a model of cochlear implantation trauma. , 2006 .

[60]  C. Dina,et al.  The gene MAPK8IP1, encoding islet-brain-1, is a candidate for type 2 diabetes , 2000, Nature Genetics.

[61]  S. Schwarze,et al.  In vivo protein transduction: delivery of a biologically active protein into the mouse. , 1999, Science.

[62]  Lee Bardwell,et al.  Interacting JNK-docking Sites in MKK7 Promote Binding and Activation of JNK Mitogen-activated Protein Kinases* , 2006, Journal of Biological Chemistry.

[63]  N. Tapon,et al.  A new Rac target POSH is an SH3‐containing scaffold protein involved in the JNK and NF‐κB signalling pathways , 1998, The EMBO journal.

[64]  A. Sharrocks,et al.  Docking domains and substrate-specificity determination for MAP kinases. , 2000, Trends in biochemical sciences.

[65]  H. K. Sluss,et al.  Selective interaction of JNK protein kinase isoforms with transcription factors. , 1996, The EMBO journal.

[66]  M. Gaestel.  Specificity of signaling from MAPKs to MAPKAPKs: kinases' tango nuevo. , 2008, Frontiers in bioscience : a journal and virtual library.

[67]  M. Bogoyevitch,et al.  The Critical Features and the Mechanism of Inhibition of a Kinase Interaction Motif-based Peptide Inhibitor of JNK* , 2004, Journal of Biological Chemistry.

[68]  Masahiko Hibi,et al.  c-Jun Can Recruit JNK to Phosphorylate Dimerization Partners via Specific Docking Interactions , 1996, Cell.

[69]  A. Prochiantz,et al.  Antennapedia homeobox peptide regulates neural morphogenesis. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[70]  E. Nishida,et al.  Molecular recognitions in the MAP kinase cascades. , 2003, Cellular signalling.

[71]  M. Czech,et al.  An essential role of the JIP1 scaffold protein for JNK activation in adipose tissue. , 2004, Genes & development.

[72]  Lee Bardwell,et al.  A Docking Site in MKK4 Mediates High Affinity Binding to JNK MAPKs and Competes with Similar Docking Sites in JNK Substrates* , 2003, Journal of Biological Chemistry.

[73]  D. Gillespie,et al.  Molecular mechanism and biological functions of c-Jun N-terminal kinase signalling via the c-Jun transcription factor. , 2002, Cellular signalling.

[74]  G. Waeber,et al.  IB1, a JIP-1-related Nuclear Protein Present in Insulin-secreting Cells* , 1998, The Journal of Biological Chemistry.

[75]  Andrew D Sharrocks,et al.  ERK5 is targeted to myocyte enhancer factor 2A (MEF2A) through a MAPK docking motif. , 2004, The Biochemical journal.

[76]  M. Bogoyevitch,et al.  Identification of the Critical Features of a Small Peptide Inhibitor of JNK Activity* , 2002, The Journal of Biological Chemistry.

[77]  G. Sumara,et al.  c-Jun/AP-1 controls liver regeneration by repressing p53/p21 and p38 MAPK activity. , 2006, Genes & development.

[78]  Chi‐Kuang Huang,et al.  Characterization of an Autoinhibitory Domain in Human Mitogen-activated Protein Kinase-activated Protein Kinase 2 (*) , 1995, The Journal of Biological Chemistry.

[79]  D. Gillespie,et al.  Analysis of the Interaction between c-Jun and c-Jun N-terminal Kinase in Vivo * , 1998, The Journal of Biological Chemistry.

[80]  T. Herdegen,et al.  Context-specific inhibition of JNKs: overcoming the dilemma of protection and damage. , 2005, Trends in pharmacological sciences.

[81]  C. Weston,et al.  The JNK signal transduction pathway. , 2007, Current opinion in genetics & development.

[82]  D. Schorderet,et al.  Cell-Permeable Peptide Inhibitors of JNK: Novel Blockers of β-Cell Death , 2001 .

[83]  C. Slaughter,et al.  Binding of JNK/SAPK to MEKK1 Is Regulated by Phosphorylation* , 2002, The Journal of Biological Chemistry.

[84]  Wei Chen,et al.  Differential regulation and properties of MAPKs , 2007, Oncogene.

[85]  M. Morris,et al.  A peptide carrier for the delivery of biologically active proteins into mammalian cells , 2001, Nature Biotechnology.

[86]  A. Vercelli,et al.  A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia , 2003, Nature Medicine.

[87]  D. Morrison,et al.  Regulation of MAP kinase signaling modules by scaffold proteins in mammals. , 2003, Annual review of cell and developmental biology.

[88]  P. Cohen,et al.  The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.

[89]  H. Saito,et al.  Conserved docking site is essential for activation of mammalian MAP kinase kinases by specific MAP kinase kinase kinases. , 2005, Molecular cell.

[90]  J. Hartwig,et al.  Actin-binding protein-280 binds the stress-activated protein kinase (SAPK) activator SEK-1 and is required for tumor necrosis factor-alpha activation of SAPK in melanoma cells. , 1997, The Journal of biological chemistry.

[91]  C. Murga,et al.  Interfering with MAP Kinase Docking Interactions: Implications and Perspectives for the p38 Route , 2007, Cell cycle.

[92]  S. Girardin,et al.  A direct interaction between JNK1 and CrkII is critical for Rac1‐induced JNK activation , 2001, The EMBO journal.

[93]  E. Nishida,et al.  Identification of a docking groove on ERK and p38 MAP kinases that regulates the specificity of docking interactions , 2001, The EMBO journal.

[94]  K. Bromberg,et al.  JAMP, a Jun N-Terminal Kinase 1 (JNK1)-Associated Membrane Protein, Regulates Duration of JNK Activity , 2005, Molecular and Cellular Biology.

[95]  J. Im,et al.  Repression of phospho‐JNK and infarct volume in ischemic brain of JIP1‐deficient mice , 2003, Journal of neuroscience research.

[96]  Lee Bardwell,et al.  Docking sites on mitogen-activated protein kinase (MAPK) kinases, MAPK phosphatases and the Elk-1 transcription factor compete for MAPK binding and are crucial for enzymic activity. , 2003, The Biochemical journal.

[97]  A. Vercelli,et al.  Time-course of c-Jun N-terminal kinase activation after cerebral ischemia and effect of D-JNKI1 on c-Jun and caspase-3 activation , 2007, Neuroscience.

[98]  J. Beckmann,et al.  Cell-permeable peptides induce dose- and length-dependent cytotoxic effects. , 2007, Biochimica et biophysica acta.

[99]  A. Sharrocks,et al.  Selective Targeting of MAPKs to the ETS Domain Transcription Factor SAP-1* , 2001, The Journal of Biological Chemistry.

[100]  Natalie A. Lissy,et al.  Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration , 1998, Nature Medicine.

[101]  L. V. von Segesser,et al.  Myocardial Ischemia/Reperfusion Injury and Infarct Size in Vivo , 2006 .

[102]  Jing Wang,et al.  Inhibition of the c-Jun N-Terminal Kinase-Mediated Mitochondrial Cell Death Pathway Restores Auditory Function in Sound-Exposed Animals , 2007, Molecular Pharmacology.

[103]  C. Peyssonnaux,et al.  Differential Regulation of B-Raf Isoforms by Phosphorylation and AutoinhibitoryMechanisms , 2006, Molecular and Cellular Biology.

[104]  M. Bernaudin,et al.  D-JNKi, a peptide inhibitor of c-Jun N-terminal kinase, promotes functional recovery after transient focal cerebral ischemia in rats , 2008, Neuroscience.

[105]  M. Gaestel,et al.  MAPKAP kinases — MKs — two's company, three's a crowd , 2006, Nature Reviews Molecular Cell Biology.